Podcasts about Retinal

Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA). For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Please visit answersincme.com/ADC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jordana Goren Fein, MD, MS. In this activity, an expert in retinal vein occlusion (RVO) reviews diagnostic best practices, newer-generation anti-VEGF therapies, and patient-centered management strategies. Upon completion of this activity, participants should be better able to: Describe best practices for diagnosing RVO; Differentiate between the clinical profiles of available newer-generation intravitreal anti-VEGF therapies for macular edema (ME) secondary to RVO; and Propose optimized, patient-centered treatment plans for the multidisciplinary management of patients with RVO.

Dr. Casandra MacLeod discusses central retinal artery occlusions, recent trials, and those anticipated in the future.  Show citation:  Préterre C, Gaultier A, Obadia M, et al. Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. Lancet Neurol. 2025;24(11):909-919. doi:10.1016/S1474-4422(25)00308-4  Poli S, Grohmann C, Wenzel DA, et al. Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial. Int J Stroke. 2024;19(7):823-829. doi:10.1177/17474930241248516  Ryan SJ, Jørstad ØK, Skjelland M, et al. A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion. N Engl J Med. 2026;394(5):442-450. doi:10.1056/NEJMoa2508515 Show transcript:  Dr. Casandra MacLeod Hello, this is Casandra MacLeod, a neurology resident at Cleveland Clinic with today's Neurology Minute. Today we will be discussing central retinal artery occlusions, or CRAOs, and the recent trials that have come out and even those further on the horizon. The 2026 American Heart Association and American Stroke Association guidelines for the early management of patients with acute ischemic stroke were recently published and in them highlight the uncertainty around the treatment of acute CRAOs with intravenous thrombolysis, even when the patient presents within four and a half hours and is otherwise eligible. These guidelines come after two recent trials, which we will further discuss. The thrombolysis in patients with acute central retinal artery occlusion, or the THEIA trial, was published in the November issue of Lancet Neurology. This multicenter trial out of France randomized 70 patients with acute CRAOs presented within four and a half hours of time from last known well to either receive IV alteplase and oral placebo or IV placebo and oral aspirin. While safety measures showed no symptomatic hemorrhage event, although they did have one asymptomatic intracerebral hemorrhage occur, the primary outcomes, which included visual acuity improvement at one month, showed some evidence for a trend of improved acuity in the IV thrombolytic group at 66% compared to 48 in the aspirin group, it did not reach significant. And now more recently, the Tenecteplase in central retinal artery occlusion study, or TenCRAOs, was published in the January 2026 issue of The New England Journal of Medicine. TenCRAOs was a six European country multicenter trial that randomized 78 patients with CRAOs all presenting within four and a half hours of time from last known well to either receive IV Tenecteplase or aspirin, both with placebo-matching as in THEIA. The primary outcomes of TenCRAOs also included visual acuity at one month, but unfortunately this trial also did not show [inaudible 00:02:07]. They showed 20% in the IV TNK group compared to 24% in aspirin. And additionally, there was one fatal intracerebral hemorrhage in the TNK group that should be considered. Overall, the AHA and ASA guidelines state the usefulness of treatment with intravenous thrombolysis is uncertain. And this is based largely on these studies as neither trial showed improved visual recovery. Although both of these trials are underpowered, leading many to believe that the jury is still out on the use of IV thrombolytics in CRAOs. But importantly, stay on the lookout for one last trial. The early reperfusion therapy with intravenous alteplase for recovery of vision and acute central retinal artery occlusion, or the Revision trial, is actively recruiting. Revision is similar in design as THEIA, but with a goal of up to 422 total patients for a goal of a well-powered study to guide decision making. 

Today's episode is a very special one. We are joined by Anna and her mother, Chelle, to discuss what it is like to live with Leber congenital amaurosis (or LCA) and to understand the patient experience of receiving retinal gene therapy with Luxturna, the first FDA approved gene therapy in medicine.  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

Drs. Yiu and Emami continue their wrap-up of the highlights from the 49th Annual Macula Society Meeting, focusing on new developments in imaging technologies, AI, and drug delivery for retinal diseases. They also touch on emerging basic science topics like the gut microbiome and metabolomics, and how these may support more personalized, systems-level approaches to eye disease.

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss…High-dose Aflibercept holds strong at 2 years for central diabetic macular edema with significantly fewer injections.Retinal disease burden in the United States is vast and unevenly distributed.Retinal imaging may serve as a noninvasive window into microvascular kidney disease.Keratoconus may be underrecognized in older adults.

In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.

In dieser Episode sprechen Hans-Dieter Höltje und Bernd Rupp über die Vitamine A, D und E. Erklärt werden die Rolle von Retinal im Sehvorgang, warum Vitamin D kein echtes Vitamin ist und die antioxidative Wirkung der Tocole.

In this episode, we discuss the use of aflibercept 8mg for the management of retinal vein occlusion and the results of the QUASAR study with Dr. Sunir Garg, Co Director of Retina Research at the Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Drs. Mohsin Ali and Akshay Thomas join to preview the May 2026 edition of Retinal Physician found online at http://www.retinalphysician.com. Discussion includes management options for diabetic retinopathy and diabetic macular edema, artificial intelligence screening for diabetic retinopathy, and the PRIMA subretinal implant.

On today’s episode of Spendy Savey, Kelly and Leigh are sharing their latest beauty obsessions, including the $3.70 Korean beauty find that targets dark circles, the "motor oil" eyeliner Leigh is surprisingly obsessed with and the cult-status hair scrub Kelly wishes she could experience for the first time all over again. Plus, Leigh explains why she’s carrying around what looks like a "dirty towel" from Amazon, and we unbox a brand-new clinical hair range that claims our scalps are aging faster than our faces... (Rude!) EVERYTHING MENTIONED: SPENDY: KELLY: Anastasia Beverly Hills Magic Touch Blush Trio in Peach, $70. LEIGH: ESK Ultimate Gold A Night Cream, $115. SAVEY: KELLY: Mary & May Tranexamic Acid + Glutathione Eye Cream, $23. LEIGH: Mecca Max Zoom Zip Liner in Motor Oil, $22. NEWBIE: KELLY: Chloé Atelier des Fleurs "The Mediterranean Essences" Collection, from $60. LEIGH: Nioxin Pro Clinical Age Defense Range, from $57. SMS/EMPTY KELLY: Christophe Robin Cleansing Purifying Scrub with Sea Salt, $72. LEIGH: Self-Adhesive Magic Cloth Makeup Bag, $22. WHAT'S ON KELLY'S FACE: Go-To Very Glowy Primer, $48. Natasha Denona HY-Glam Foundation (N3), $94. Anastasia Beverly Hills Magic Touch Blush Trio in Peach, $70. Rare Beauty Warm Wishes Soft Matte Powder Bronzer in Sun Blaze, $51. Holme Beauty Soft Set Eye Primer in Blanche, $35. Sephora Collection 12H Intense Ink Classic Line Felt Eyeliner in Espresso, $24. Benefit Precisely My Brow in 3.5, $49. W7 Tube It Mascara, $6.99. Makeup By Mario Surrealskin™ Soft Setting Spray, $72. Laneige Juicepop Box Lip Tint in 06 Classic Red, $ 30. DON'T FORGET: Win a $2,000 Bed Threads voucher. Subscribe to Mamamia here before April 30 to be automatically entered. Current subscriber? You're already in the draw. T&Cs apply. Watch & Subscribe on YouTube, this episode drops tonight at 7pm! Catch it here. Follow us on Instagram: @youbeautypodcast Follow us on TikTok: @youbeautypod Join our You Beauty Facebook Group here GET IN TOUCH: Got a beauty question you want answered? Email us at youbeauty@mamamia.com.au or send us a voice note on Instagram! You Beauty is a podcast by Mamamia. Listen to more Mamamia podcasts here. For our product recommendations, exclusive beauty news, reviews, articles, deals and much more - sign up for our free You Beauty weekly newsletter here Subscribe to Mamamia here CREDITS: Hosts: Kelly McCarren & Leigh Campbell Producer: Zara Sengstock & Ella Maitland Audio Producer: Tegan Sadler Video Producer: Artemi Kokkaris Just so you know - some of the links in these notes are affiliate links, which means we might earn a small commission if you buy through them. It doesn’t cost you anything extra, and it helps support the show. Happy shopping! Mamamia acknowledges the traditional owners of the land on which we have recorded this podcast.Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Dr. Mitul Mehta joins to share career perspectives in retina and wearable technology for retinal disease, including his company Eyedaptic.Dr. Mehta does have a financial disclosure for Eyedaptic.

Broadcast from KSQD, Santa Cruz on 4-09-2026: Dr. Dawn shares a follow-up from an emailer in Switzerland providing seven functional medicine practitioner addresses near Zurich and Aargau, noting that Switzerland uses different terminology but is actually an "epicenter of functional medicine." Dr. Dawn calls for support of the bipartisan Break Up Big Medicine Act, modeled on Glass-Steagall, which would prohibit common ownership of medical providers with insurers, pharmacy benefit managers, or drug wholesalers. She explains how vertical integration by companies like UnitedHealth, CVS/Aetna, and Cigna allows them to game medical loss ratio requirements through self-dealing while driving up costs. A European clinical trial implanted 2mm x 2mm light sensors beneath the retinas of 38 people with advanced macular degeneration, with 80% gaining clinically meaningful improvement (two lines on the vision chart) after one year. The device bypasses damaged rods and cones, sending camera images from glasses directly to the optic nerve. Dr. Dawn explains that air temperature warnings are measured in shade, but direct sunlight can add 20°C to heat exposure. Heat stroke triggers gut permeability, releasing lipopolysaccharides that cause cytokine storms and organ failure. She advises fans over air conditioning when possible, shade, hydration, and loose natural-fabric clothing. An emailer asks if low-dose oral strontium supplementation has the same problem as pharmaceutical strontium. Dr. Dawn confirms it improves bone density scores without reducing fracture risk, and recommends telopeptide testing to monitor actual bone loss after discontinuing. An emailer's doctor wants to prescribe high-dose dexamethasone for low platelets. Dr. Dawn advises against rushing to steroids since platelets of 40 are adequate for clotting, recommending a hematology consultation and repeat testing with citrated blood. Dr. Dawn reviews fiber types: wheat dextrin (Benefiber) is fermentable but technically gluten-free; guar fiber (Sunfiber) ferments slowly and works for low-FODMAP diets; inulin feeds bifidobacteria and produces anti-inflammatory short-chain fatty acids; methylcellulose (Citrucel) is non-fermentable; and psyllium (Metamucil) is facing a class action lawsuit over undisclosed lead contamination. An emailer with varicose veins reports recurring superficial blood clots. Dr. Dawn explains these don't travel to lungs like deep vein clots, but repeated clotting suggests possible thrombophilia requiring workup. She recommends consulting a vascular surgeon about superficial venous ligation under local anesthesia. Analysis of 25,000 wearable users found that three daily "exercise snacks" of just 1-2 minutes of vigorous activity (stairs, running for a bus) reduced all-cause mortality by 38-40%. Benefits plateau around 7,500 steps daily, and simply standing up every couple of hours dramatically reduces sedentary risks.

CME credits: 1.00 Valid until: 10-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/ This rebroadcast of a live regional meeting series, part of The Focused Sight Initiative: Quality Improvement Interventions in Retinal Diseases, brings together retina specialists and eye care professionals to address systemic gaps in the timely diagnosis, referral, and management of patients with retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Faculty discuss the clinical consequences of treatment delays, highlight real-world challenges to intravitreal anti-VEGF therapy adherence, and examine disparities in access to care. Learners will explore best practices for identifying patients at risk for progression, optimizing referrals from optometry to retina specialists, and implementing patient-centered communication strategies to improve outcomes. Emphasis is placed on leveraging imaging tools for earlier detection, addressing cultural and socioeconomic barriers, and adopting practice-level interventions to reduce loss to follow-up.=

In this episode, we are diving deep into the retinal (retinaldehyde) landscape to see how current market offerings stack up. Following our technical breakdown of retinol versus retinal, we shift our focus to real-world testing of popular formulations from Krave Beauty, Prequel, Celimax, and Medik8. We examine the scientific validity of concentration ranges—from the entry-level 0.05% to the more intense 0.24%—and discuss how different textures and price points impact the user experience for various skin types. Whether you are a retinoid rookie or a seasoned pro, we provide the detailed assessment on the data to find the right one for your particular skinario.   Timestamps: 00:00 - Intro 02:18 - Product Aesthetics & Textures 08:35 - Krave Beauty 24 Retinal Decode 10:21 - Prequel Retinal Renewal Decode 15:48 - Celimax Vita-A Retinal Shot Decode 22:00 - Medik8 Crystal Retinal 6 Decode 23:51 - Is Retinal 11x faster than Retinol? 28:39 - Chemists' Favorite Retinal (Personal favorites and usage recommendations)   Products Mentioned: Shop everything mentioned in this video here: https://shopmy.us/collections/4698294 PREQUEL | Retinal Renew Retinaldehyde Gel: https://go.shopmy.us/p-51236222 CELIMAX | The Vita-A Retinal Shot Tightening Booster: https://go.shopmy.us/p-51236269 KRAVEBEAUTY | 24 Carrot Retinal Gentle 0 05 Retinal Serum: https://go.shopmy.us/p-51236391 MEDIK8 | Crystal Retinal 6 Serum: https://go.shopmy.us/p-51236422 (use code: CHEMISTCONFESSIONS for 15% off) Shop more of my favorite products here: https://shopmy.us/chemistconfessions    

Dr. Rukhsana Mirza sits down with Dr. Avni P. Finn to discuss her Ophthalmology Science article, "Ultra-Widefield Fundus Autofluorescence Findings as an Indicator of Duration in Rhegmatogenous Retinal Detachment," which used ultra-widefield color fundus photography and fundus autofluorescence to assess patients with rhegmatogenous retinal detachment, relating clinical features to imaging findings and comparing between the 2 imaging modalities. Ultra-Widefield Fundus Autofluorescence Findings as an Indicator of Duration in Rhegmatogenous Retinal Detachment. Zhang, David L. et al. Ophthalmology Science, Volume 6, Issue 2. Working on new research? Researchers around the world are already submitting abstracts for AAO 2026. If you're preparing a paper, poster, or video, now is the time to share it. Abstract submissions close April 14. Submit your abstract today. Visit aao.org/pod26.

Send us Fan MailIn this Journal Club episode, Ben and Daphna explore an exciting new frontier in neonatology: oculomics. Reviewing a recent paper from JAMA Ophthalmology, they discuss how deep learning models applied to routine ROP screening images can predict the development of BPD and pulmonary hypertension in preterm infants. By combining visual features extracted via neural networks with standard demographic data, researchers achieved impressive predictive accuracy weeks before clinical diagnosis is typically made. Tune in to hear how the eyes might just be the window to the neonatal pulmonary vasculature!----Deep Learning-Based Prediction of Cardiopulmonary Disease in Retinal Images of Premature Infants. Singh P, Kumar S, Tyagi R, Young BK, Jordan BK, Scottoline B, Evers PD, Ostmo S, Coyner AS, Lin WC, Gupta A, Erdogmus D, Chan RVP, McCourt EA, Barry JS, McEvoy CT, Chiang MF, Campbell JP, Kalpathy-Cramer J.JAMA Ophthalmol. 2026 Jan 22:e255814. doi: 10.1001/jamaophthalmol.2025.5814. Online ahead of print.PMID: 41569552Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

We are diving back into the "rumor mill" of the retinoid world! Is Retinal actually better than Retinol, or is it just better marketing? In this episode, we revisit the Retinol vs. Retinal debate with new 2026 data. We break down what the evidence says about the retinoid conversion pathway into retinoic acid. We look at the latest clinical evidence to help you decide if it's time to switch your anti-aging active or stay the course with your current skincare routine. Episode Timestamps 0:00 - Intro: Revisiting the Retinoid Rumor Mill 1:34 - Why Retinal (Retinaldehyde) is Growing in Popularity 2:01 - The Science of Retinoic Acid Conversion Steps 5:30 - What the Data Shows (Retinol vs. Retinal ex vivo Conversion) 9:15 - Retinal vs. Retinol: Potency & Efficacy Realities 14:40 - Is Retinal Actually Gentler? (Irritation & Skin Barrier) 18:20 - Debunking High-Concentration Retinoid Myths 23:55 - Reviewing Recent Retinal Product Launches 28:10 - How to Choose: Retinol or Retinal for your Skin Type? 36:22 - Final Verdict: Should You Switch Your Active? Resources & Mentions Retinal vs Retinol on the CC Blog: https://chemistconfessions.com/blogs/retinal-is-it-better-than-retinol Retinol vs Tretinoin: https://chemistconfessions.com/blogs/tretinoin-vs-retinol Follow us on IG : @chemist.confessions #chemistconfessions #retinal #retinol #skincarescience #antiaging #retinaldehyde #skincareroutine

Host: Darryl S. Chutka, M.D.  Guest: Brittni A. Scruggs, M.D., Ph.D.  There are a variety of eye disorders which involve the retina, and they all have the potential to cause significant vision loss or blindness if not detected early. Two of the most common retinal disorders we see in primary care include diabetic retinopathy and macular degeneration. Since most health conditions affecting the retina are asymptomatic early in their course making patient screening and risk factor management an important task for primary care clinicians. Appropriate referrals to an ophthalmologist can result in effective treatment and improved outcomes. Which patients are at risk of retinal disorders? What are some “red flag” symptoms which should give us concern? Which medications we prescribe can affect the retina? This podcast is about retinal disorders, and I'll be asking these questions and more of my guest, Dr. Brittni Scruggs, an ophthalmologist and retinal surgeon at the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Dr. Lynn Hellerstein of Vision Beyond Sight sits down with Dr. Amy Laster, neuroscientist & Chief Scientific Officer at the Foundation Fighting Blindness that advances cures for retinal diseases, to talk about bridging cutting-edge science with human connection and leading the Foundation Fighting Blindness to accelerate research for rare eye diseases. As a neuroscientist-turned-nonprofit leader, she shares how translating complex science into human impact is advancing treatments – while keeping patients, families, and possibility at the heart of every breakthrough. Dr. Laster shares her journey from neuroscience into nonprofit leadership, revealing how her “superpower” of big-picture strategic thinking helps drive research forward more efficiently. Together, they unpack what retinal diseases are, the scope of their impact—from rare inherited conditions to age-related macular degeneration—and the innovative therapies offering new hope. From gene augmentation treatments like Luxturna to emerging clinical trials in retinal cell transplantation, this conversation bridges complex science with real-world impact. You'll also hear powerful patient stories, including Rebecca Alexander's experience with Usher syndrome and Lindsey Rambo's groundbreaking role in early gene therapy trials. Beyond the lab, Dr. Laster highlights the importance of community, family support, and ensuring patients remain at the heart of every scientific advance. She also discusses the Foundation's ambitious 5-year strategic plan and the evolving ways they measure success—including new technologies like virtual reality testing and using focal points of light. This episode is a compelling look at how innovation, empathy, and purpose are shaping the future of vision science—and why no one facing vision loss has to navigate it alone. Dr. Lynn Hellerstein, Developmental Optometrist, co-owner of Hellerstein & Brenner Vision Center, P.C., award-winning author and international speaker, holds powerful and inspiring conversations with her guests in the areas of health, wellness, education, sports and psychology. They share their inspirational stories of healing and transformation through their vision expansion. Vision Beyond Sight Podcast will help you see with clarity, gain courage and confidence. Welcome to Vision Beyond Sight! Also available on Apple Podcasts, iTunes, Google Podcasts, Spotify, iHeart Radio, Audible and Stitcher.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QKV865. CME/AAPA credit will be available until April 3, 2027.Innovations in Retinal Vascular Diseases: Enhancing Patient Outcomes Through Longer-Acting Therapies and Precision Dosing In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Interview with T. Y. Alvin Liu, MD, author of Prevalence and Health Care Disparities of Retinal Conditions: A Meta-Analysis. Hosted by Neil Bressler, MD. Related Content: Prevalence and Health Care Disparities of Retinal Conditions

Interview with T. Y. Alvin Liu, MD, author of Prevalence and Health Care Disparities of Retinal Conditions: A Meta-Analysis. Hosted by Neil Bressler, MD. Related Content: Prevalence and Health Care Disparities of Retinal Conditions

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - New Class on the Spirituality of Naturopathy 00:04:05 - Chronic Fatigue - Balance Issues - Brain Fog 00:35:14 - Adenoidectomy - Tonsillectomy 00:45:27 - Retinal Detachment and Degeneration, Corneal Thinning/ Bloating - Low Thyroid 01:08:16 - Chronic Pain - Healing Journey  01:24:42 - Breast Tumor 00:04:05 - Chronic Fatigue - Balance Issues - Brain Fog For the last 7 years, I've had an on and off feeling, like I'm on a boat when walking. 00:35:14 - Adenoidectomy - Tonsillectomy I deeply regret this. Can they grow back? 00:45:27 - Retinal Detachment and Degeneration, Corneal Thinning/ Bloating - Low Thyroid Is it possible to regenerate retinas and the eyes structure, damaged through treatments? 01:08:16 - Chronic Pain - Healing Journey  I want to snack on fruit during the day, but the gas/bloat makes me embarrassed. 01:24:42 - Breast Tumor I started to have a kind of a cyst on the left breast, it's now up to 7-9 cm in diameter.

Learn the symptoms of retinal and ocular migraines, such as twinkling, shimmering, or flashing lights in the visual field, which are classic symptoms of both retinal and ocular migraines. ​Some differences include: retinal migraines typically affect only​ one eye and are more serious, while ocular migraines (migraine with aura) usually affect both eyes​ and involve zigzags or blind spots. For more episodes of Ageless Health® with Dr. Tom Roselle, DC please visit: https://www.drtomroselle.com/ageless-health-podcast/ #AgelessHealth @DrTomRoselleDC @WMALDC @RoselleCare #AppliedKinesiology #RoselleCenterForHealing #HolisticHealth #IntegrativeHealth #FunctionalMedicine #HealthEducation #chronicheadaches #migraines #botox #intermittentfasting #retinalmigraine #ocularmigraine

Drs. Kat Talcott and Priya Vakharia join to discuss the March 2026 edition of Retinal Physician, including bicistronic gene therapy, photobiomodulation, uveitis fellowships, and polypoidal vascular choroidopathy. Listeners, as we approach our 500th episode, we will be having a Q&A session featuring questions and thoughts from you! It's your chance to have your voice heard on the podcast.Please record an audio / video of your question and upload it to the linked form (https://forms.gle/nyv3fvCHZJ4XzQe67). We are excited to hear what you have to say!

02-24-26 - Obama On Podcast Confirmed We've Seen Aliens - Holmberg Explains What Happened To Prompt His Retinal Surgery And Encourages People To Have Their Eyes CheckedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

02-24-26 - Obama On Podcast Confirmed We've Seen Aliens - Holmberg Explains What Happened To Prompt His Retinal Surgery And Encourages People To Have Their Eyes CheckedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meaningful improvement in vision at one year with Dr. Daniel Palanker, Professor of Ophthalmology and Electrical Engineering, Stanford University.

This episode we get into a new JAMA Ophthalmology study takes a hard look at pickleball-related eye injuries, and the numbers are… not great. Retinal detachments, hyphemas, orbital fractures, and even open globes are showing up more and more, especially as the sport explodes in popularity among older adults. I break down exactly how these injuries happen, which ones are true emergencies, and why I am once again begging you, politely, but firmly, to wear eye protection while playing pickleball Takeaways: Why pickleball-related eye injuries have surged dramatically in the last few years and why 2024 alone accounted for a huge chunk of them. How a single blunt hit from a pickleball can lead to retinal tears, detachments, or bleeding inside the eye. The most common orbital fracture caused by blunt eye trauma and why age actually changes how dangerous it is. When blood in the eye (hyphema) turns from “watch and wait” into a full-on pants-on emergency. The simplest, cheapest way to avoid becoming an ophthalmology case study: wear safety glasses, especially if your reaction time isn't what it used to be. To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Go to Cozy Earth now for a Buy One Get One Free Pajama Offer from 1/25-2/8! Yes, go to cozyearth.com they are doing a BOGO pajama promo. Just use my Code: KNOCKKNOCKBOGO Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's episode of Kelsey Unpacked, we're talking Skincare in the Air, aka my fun travel tradition with my daughter. If we're on an early morning flight, we pull out our toiletry bag and do our skincare right there in our seats.I'm sharing the tools and products that are actually making a difference for my skin in my 40s, plus my must-haves that make it into my toiletry bag. Also sharing the few things I genuinely can't live without.Buy Me A Coffee: https://buymeacoffee.com/kelseygravesFollow me on Instagram: https://www.instagram.com/kelsey_gravesFollow me on TikTok: https://www.tiktok.com/@mskelseygravesJoin us in the Trip Tales Podcast Community Facebook Group: https://www.facebook.com/groups/1323687329158879Mentioned in this episode:- SHOP skincare products on my ShopMy page: https://shopmy.us/collections/public/3657421- Megelin LED Red Light Therapy Face Mask- Medicube Kojic Acid Tumeric Glycolic Acid Pads- Therabody Theraface Depuffing Wand- Maskiss 24K Gold Eye Masks- Cetaphil Gentle Face Cleanser- La Roche-Posay Thermal Water Spray- Tule 'Spresso Energizing Eye Balm- Uncommon Beauty Glutathione Serum- Pacifica Glow Baby Serum- Youth the the People: Triple Peptide Hyaluronic Acid & Retinal and Niacinamide- Olay Pro Advanced Regenerist- La Roche-Posay Tinted Mineral Sunscreen- Hydrafacial- Dysport

Dr. Natalia Vergara is an Assistant Professor of Ophthalmology at the Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine on the Anschutz Medical Campus. Natalia uses stem cells to understand how the retina forms during development and how it degenerates during disease with the goal of developing therapies to help patients who suffer from vision loss. For her research, Natalia uses a type of stem cells called induced pluripotent stem cells which can be reprogrammed so they can form any type of cell in the body. With these cells, they can make human retina tissue using any individual's cells in a petri dish in the lab to better understand diseases, test treatments, and potentially prepare retinas for transplant. In her free time, Natalia loves hanging out, cooking, and enjoying food with friends and family, including her husband and two young kids. Natalia is also an avid traveler, and she delights in the thrill of discovery that comes along with exploring new places. Natalia received her B.S. in biochemistry from the National University of the Litoral in Argentina. She worked as an instructor and research intern at the National University of Entre Ríos for about three years before beginning graduate school. Natalia was awarded her PhD in retinal regenerative biology from Miami University in Ohio. Afterwards, she conducted postdoctoral research at the Wilmer Eye Institute of Johns Hopkins School of Medicine. She served as a Research Associate Faculty member at Johns Hopkins School of Medicine for about two years before joining the faculty at the University of Colorado. Natalia has received awards for research and for mentoring, including the Ruben Adler Research Award from the Wilmer Eye Institute at Johns Hopkins University School of Medicine in 2012, and she was selected as an Emerging Vision Scientist to participate in the Third Annual EVS day on Capitol Hill by the National Alliance for Eye and Vision Research in 2017. In our interview, Natalia tells us more about her life and science.